research Artificial Intelligence in Dermatology: Crossing the Frontier.
AI can greatly improve skin cancer diagnosis and treatment.
Search
for
Sort by
Research
420-450 / 1000+ results
research Efficacy and Safety of Tofacitinib in Paediatric Alopecia Aerata - A Prospective Observational Study
Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
research Journal of Population Therapeutics and Clinical Pharmacology
Baricitinib is more effective than methotrexate for severe alopecia areata.
research 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research Effective treatment of alopecia universalis with oral tofacitinib: A case report
Oral tofacitinib successfully treated total body hair loss in one patient.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Balancing Benefits and Limitations of Artificial Intelligence in Cosmetic Surgery
AI improves cosmetic surgery but requires ethical and legal oversight to ensure safe use.
research Optimizing Skin Quality via AI-Enhanced Physical Activity
AI can personalize exercise to improve skin health.
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
research Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
research Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
research Janus kinase inhibitor as a therapeutic option in alopecia areata. Case report
JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
research Epitopes, avidity and IgG subclasses of tyrosine hydroxylase autoantibodies in vitiligo and alopecia areata patients
TH antibodies in vitiligo and AA patients recognize the same protein parts.
research Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy
Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
research Alopecia areata
Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
research Acne exacerbation after tofacitinib treatment for alopecia areata
Tofacitinib treatment for hair loss may worsen acne.
research AI06 ALUDWIG: an automated artificial intelligence-based assessment of female androgenic alopecia
ALUDWIG can help standardize female hair loss assessment from a single image.
research Can Artificial Intelligence Support Patient Education in Scabies? A Comparative Analysis of Large Language Model Responses
AI chatbots can help with scabies education but shouldn't replace doctors.
research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research Baricitinib-loaded separable microneedle array patch (S-MAP) based on hyaluronic acid for alopecia areata therapy
The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Trichothiodystrophy with Dysmyelination and Central Osteosclerosis
Specific brain and bone imaging findings can help diagnose Trichothiodystrophy.
research 448 Challenges of securing insurance approval for oral tofacitinib treatment of alopecia areata: A multi-institutional retrospective review
Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
research Tether-induced tenosynovitis: The importance of an intact skin barrier
An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
research Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
Tofacitinib helped a woman with total-body hair loss grow her hair back.
research Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 weeks
Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.
research SZTUCZNA INTELIGENCJA W MEDYCYNIE: WIĘCEJ PYTAŃ NIŻ ODPOWIEDZI
AI in medicine raises many questions and concerns.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata
Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
research Beard hair response in Alopecia Areata Universalis treated with baricitinib
Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.